Streetbeat News

Products Services

MULN

Mullen Automotive (NASDAQ:MULN) has launched an electric vehicle (EV) pilot program with the New York Power Authority (NYPA). The program involves testing Mullen's EV Cargo Van, the all-electric Campus Delivery Utility Vehicle, at NYPA's location in upstate New York. The move aligns with NYPA's 2030 Vision of a carbon-free New York State powered by clean energy.

Portfolio Pulse from Happy Mohamed

July 13, 2023 | 12:12 pm

WKSP

Worksport Ltd. has received $720,000 in purchase orders for its soft-folding tonneau covers.

Portfolio Pulse from Benzinga Newsdesk

July 13, 2023 | 12:11 pm

AZN

Health Canada has granted AstraZeneca a Notice of Compliance with conditions for Lynparza in combination with Abiraterone and Prednisone or Prednisolone. The conditional approval is based on data from the Phase 3 Propel trial.

Portfolio Pulse from Benzinga Newsdesk

July 13, 2023 | 12:11 pm

ACIW

ACI Worldwide (NASDAQ:ACIW) and Security Bank Corporation have partnered to revolutionize the Bank's real-time payment hub. Security Bank will implement ACI's cloud-native Enterprise Payments Platform solution, unifying its payments platform and facilitating interoperability of payment services. The modernized payment hub will allow Security Bank to roll out innovative products and services faster. Real-time payment transactions in the Philippines are expected to grow from 625 million in 2022 to 1.5 billion by 2027, representing a CAGR of 18.7%.

Portfolio Pulse from Happy Mohamed

July 13, 2023 | 12:09 pm

QUBT

Quantum Computing Inc. (QUBT) has received a third subcontract award from NASA, via the Bay Area Environmental Research Institute (BAERI), to build and test a photonic sensor instrument for atmospheric particulate measurement. The sensor is expected to be delivered in Q1 2024. The technology could have applications in industrial, civilian, and defense sectors. This is the third distinct task order from NASA in four months, highlighting QCi's core proprietary photonic capability.

Portfolio Pulse from Happy Mohamed

July 13, 2023 | 12:09 pm

DV

ROKU

DoubleVerify (DV) and Roku have announced they will continue to collaborate and conduct investigations into emerging ad fraud schemes within the TV streaming industry. This follows their success in neutralizing SmokeScreen, a sophisticated ad fraud scheme. The companies aim to identify and curb new fraud schemes, preserving advertiser confidence and securing the integrity of the CTV advertising ecosystem. They will leverage Roku's Advertising Watermark technology and DV's Fraud Lab and anti-fraud solutions.

Portfolio Pulse from Happy Mohamed

July 13, 2023 | 12:08 pm

AKTX

Akari Therapeutics (NASDAQ:AKTX) has announced updates on the development of nomacopan for treating pediatric and adult hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The company is on track to begin patient enrollment in a Phase 3 study of nomacopan in pediatric HSCT-TMA by the end of 2023. It also plans to start a Phase 3 double-blind placebo-controlled clinical trial of nomacopan in adult HSCT-TMA in 2024. The FDA has granted Orphan Drug, Fast Track, and Rare Pediatric Disease designations for nomacopan in pediatric HSCT-TMA.

Portfolio Pulse from Happy Mohamed

July 13, 2023 | 12:04 pm

MDVL

MedAvail Holdings, Inc. (NASDAQ:MDVL), a pharmacy technology company, has announced successful integration between its Remote Dispensing System and its largest partner, Texas Health Resources.

Portfolio Pulse from Benzinga Newsdesk

July 13, 2023 | 12:02 pm

FICO

Global analytics software firm FICO has been granted 9 new patents, including 3 foreign and 6 U.S. patents, related to digital decisioning in the areas of fraud, artificial intelligence (AI), and machine learning technology. These patents are used in FICO's platform and fraud solutions, enhancing their value to enterprises.

Portfolio Pulse from Benzinga Newsdesk

July 13, 2023 | 12:01 pm

OSA

ProSomnus, Inc. (NASDAQ:OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (OSA), has announced plans to design a head-to-head clinical trial comparing its precision oral appliance therapy (OAT) and hypoglossal nerve stimulation (HNS) in treating patients with severe OSA.

Portfolio Pulse from Benzinga Newsdesk

July 13, 2023 | 12:01 pm